#1 Clinical Trials Search in Europe

Bleomycin

Bleomycin, a potent antineoplastic drug, is being extensively studied in various clinical trials for its potential in treating different types of cancers and vascular malformations. This article explores the latest research on Bleomycin’s applications, efficacy, and safety across multiple medical conditions, highlighting its versatility in modern cancer therapy.

Table of Contents

What is Bleomycin?

Bleomycin is an anticancer drug derived from the bacterium Streptomyces verticillus[1]. It’s known by several names, including Zeocin[2]. Bleomycin is used to treat various types of cancers and has also shown effectiveness in treating certain non-cancerous conditions.

What Conditions Does Bleomycin Treat?

Bleomycin is used to treat a variety of conditions, including:

  • Cancer: It’s used in the treatment of several types of cancer, including:
    • Germ cell tumors[1]
    • Lymphoma[1]
    • Testicular cancer[1]
    • Gastric (stomach) cancer[3]
  • Vascular malformations: These are abnormal clusters of blood vessels. Bleomycin is used to treat:
    • Venous malformations (abnormal veins)[4]
    • Lymphatic malformations (abnormal lymph vessels)[2]
    • Hemangiomas (benign tumors made of blood vessels)[5]
  • Skin conditions:
    • Cutaneous warts[6]
    • Keloid and hypertrophic scars[7]

How Does Bleomycin Work?

Bleomycin works in several ways to treat different conditions:

  • Cancer treatment: Bleomycin causes breaks in the DNA of cancer cells. This damage prevents the cells from dividing and eventually leads to their death[1]. One molecule of bleomycin can cause 10-15 DNA strand breaks, making it a potent anticancer drug.
  • Vascular malformations: When injected into abnormal blood vessels, bleomycin acts as a sclerosing agent. This means it irritates the inside of the blood vessels, causing them to close off and eventually be reabsorbed by the body[4].
  • Warts: For warts, bleomycin is believed to work by damaging the DNA of the virus causing the wart, as well as affecting the blood supply to the wart[6].

How is Bleomycin Administered?

Bleomycin can be administered in several ways, depending on the condition being treated:

  • Intravenous (IV) injection: For cancer treatment, bleomycin is often given through a vein[1].
  • Intralesional injection: For conditions like warts or vascular malformations, bleomycin is injected directly into the affected area[6][4].
  • Electrochemotherapy: This is a newer method where bleomycin is given intravenously, followed by brief electrical pulses applied to the tumor. This temporarily increases the tumor cells’ permeability, allowing the bleomycin to enter more effectively[8].

Potential Side Effects

Like all medications, bleomycin can cause side effects. Some potential side effects include:

  • Skin reactions: About half of patients may experience skin-related side effects such as redness, skin darkening, or soreness[1].
  • Lung reactions: About one in ten patients may experience lung-related side effects. In rare cases (about 1%), this can progress to a serious condition called pulmonary fibrosis[1].
  • Other side effects: These can include fever, loss of appetite, and fatigue.

It’s important to note that the risk of side effects can increase with higher doses of bleomycin. Your doctor will carefully consider the benefits and risks when prescribing this medication.

Current Research and New Applications

Researchers are continually studying bleomycin to find new uses and improve its effectiveness. Some areas of current research include:

  • Reduced dosage: Studies are investigating whether lower doses of bleomycin can be as effective while reducing side effects[8].
  • Electrochemotherapy: This technique is being studied for treating various types of cancer, including gastric cancer[3].
  • Scar treatment: Researchers are investigating the use of bleomycin for treating various types of scars[7].

These ongoing studies aim to expand our understanding of bleomycin and potentially improve its use in treating various conditions.

Aspect Details
Primary Uses Treatment of various cancers (vulvar, gastric, cutaneous), vascular malformations, hemangiomas
Mechanism of Action Causes DNA strand breaks in cancer cells, leading to cell death
Delivery Methods Intravenous, intralesional injection, combined with electroporation (electrochemotherapy)
Dosage Range Varies by condition; from 7,500 IU/m² to 15,000 IU/m² in different trials
Common Side Effects Skin reactions (erythema, hyperpigmentation), pulmonary reactions
Serious Side Effects Pulmonary fibrosis (rare, about 1% of cases)
Ongoing Research Efficacy in various cancer types, optimal dosing, combination with other treatments
Quality of Life Impact Being assessed in multiple trials using various questionnaires (EORTC QLQ-C30, FACT-V, EQ-5D-5L)

FAQ

  • What is Bleomycin and how does it work? Bleomycin is an antineoplastic drug derived from Streptomyces verticillus. It works by causing DNA strand breaks in cancer cells, leading to cell death. Bleomycin is particularly effective when used in combination with electroporation, which increases cell membrane permeability and enhances drug uptake.
  • In which types of cancers is Bleomycin being studied? Bleomycin is being investigated in clinical trials for various cancers, including vulvar cancer, gastric cancer, and cutaneous malignancies. It's also being studied for the treatment of vascular malformations and hemangiomas.
  • What is electrochemotherapy and how does it involve Bleomycin? Electrochemotherapy is a treatment that combines chemotherapy (often using Bleomycin) with electroporation. Electric pulses are applied to the tumor area shortly after Bleomycin administration, which increases the drug's ability to enter cancer cells, enhancing its effectiveness.
  • Are there any side effects associated with Bleomycin treatment? Common side effects of Bleomycin can include skin reactions (such as erythema, hyperpigmentation, and soreness) and pulmonary reactions. In rare cases (about 1%), patients may develop pulmonary fibrosis. The risk of side effects may increase with higher cumulative doses.
  • How is Bleomycin being used in non-cancer treatments? Bleomycin is also being studied for the treatment of vascular malformations, particularly venous and lymphatic malformations. It's used as a sclerosing agent in these cases, often showing promising results with fewer local serious adverse events compared to other treatments.

Ongoing Clinical Trials on Bleomycin

  • Study Comparing Electrochemotherapy with Bleomycin to Standard Radiotherapy for Treating Basal Cell Carcinoma in Patients with Tumors Less Than 3 cm

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study Comparing Chemotherapy Options for Patients with Stage I Testicular Cancer: Bleomycin, Etoposide, Cisplatin vs. Carboplatin

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway Sweden

  • Study on Reducing Bleomycin Dose in Electrochemotherapy for Patients with Skin Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Ireland The Netherlands Portugal Slovakia +1

  • Study on Electrochemotherapy with Bleomycin for Patients with Colorectal Cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Organ Preservation in Advanced Rectal Cancer Patients Using Bleomycin and Electrochemotherapy After Initial Treatment

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Blood Vessel Changes in Basal Cell Carcinoma Patients Treated with Bleomycin or Drug Combination

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Electrochemotherapy with Bleomycin and Cisplatin for Treating Vulvar Paget’s Disease and Precancerous Lesions in Newly Diagnosed or Recurrent Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of Calcium Chloride and Bleomycin with Electroporation Techniques for Patients with Unresectable Pancreatic Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Hungary Italy +3

Glossary

  • Electroporation: A technique that uses brief electrical pulses to increase the permeability of cell membranes, allowing drugs like Bleomycin to enter cells more easily.
  • Electrochemotherapy: A cancer treatment that combines chemotherapy (often Bleomycin) with electroporation to enhance drug uptake by tumor cells.
  • Vascular malformation: An abnormal development of blood vessels that can occur anywhere in the body, often treated with sclerosing agents like Bleomycin.
  • Sclerosing agent: A substance used to create scar tissue and close off blood vessels, often used in treating vascular malformations.
  • Cutaneous malignancy: A type of skin cancer or skin metastasis from other cancers that occurs in the skin layers.
  • Hemangioma: A benign (non-cancerous) tumor made up of blood vessels, often appearing as a red birthmark.
  • Pulmonary fibrosis: A rare but serious side effect of Bleomycin, characterized by scarring of lung tissue leading to breathing difficulties.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy.
  • Quality of life (QoL): A measure of an individual's well-being and ability to perform daily activities, often assessed in cancer treatment studies.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.

References

  1. https://clinicaltrials.gov/study/NCT01873326
  2. https://clinicaltrials.gov/study/NCT06437158
  3. https://clinicaltrials.gov/study/NCT04139070
  4. https://clinicaltrials.gov/study/NCT01347294
  5. https://clinicaltrials.gov/study/NCT06080724
  6. https://clinicaltrials.gov/study/NCT05023408
  7. https://clinicaltrials.gov/study/NCT04046679
  8. https://clinicaltrials.gov/study/NCT06647342